Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × darolutamide × 90 days × Clear all

Phase

Phase 2 10 Phase 1 9 Phase 3 6 Phase 4 3 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Bulbo-Spinal Atrophy, X-Linked 1

Interventions

pembrolizumab 91 Carboplatin 53 Cyclophosphamide 49 Nivolumab 45 Specimen Handling 41 Magnetic Resonance Spectroscopy 38 Biopsy 38 fludarabine 36 Gemcitabine 35 Bevacizumab 35 Dexamethasone 34 Paclitaxel 32 venetoclax 30 Temozolomide 29 Cisplatin 29 atezolizumab 27 Injections 24 Irinotecan 22 Rituximab 21 Pemetrexed 21 Docetaxel 19 Radiotherapy 18 Prednisone 18 Lenalidomide 17 Fluorouracil 17 Cetuximab 17 Azacitidine 17 durvalumab 16 Oxaliplatin 16 abemaciclib 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07190300 2026-03-02

TulmiSTAR-02

Novartis

Phase 1/2 Recruiting

Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon ⚡